News

Evotec has granted Takeda exclusive rights to a novel target in Alzheimer’s disease, based on successful target identification and validation work, triggering a milestone payment of a few

Under the agreement, Antares will apply its advanced transdermal delivery (ATD) gel platform to create a new, branded pharmaceutical product. Antares will recognize R&D revenue from this work,

Assuming the success of the safety and tolerability phase of the testing process, the company plans to begin trials evaluating the efficacy of the compound in mid-2006. “This

Boston Scientific is proposing to pay $72 per Guidant share in a combination of cash and stock, a price which is approximately 14% higher than the $63.43 value

The phase I/II trial is being initiated at The University of Texas MD Anderson Cancer Center, and is the first time researchers will be able to test the

The compound is a tumor necrosis factor alpha (TNF-alpha) antagonist for rheumatoid arthritis (RA) derived from Borean’s proprietary C-Type Lectin Domain (CTLD) library of therapeutic proteins. The study

The patent covers the core of the Oriel technology including design of Oriel’s dry powder inhalers containing multi-dose dry powder packages that can individually be activated to vibrate

Ribavirin is a synthetic nucleoside analogue with antiviral activity currently marketed by Roche Pharmaceuticals under the brand name Copegus. Annual US sales of the product are approximately $200

The study evaluated more than 1,700 Alzheimer’s cases and more than 1,700 age-matched controls. Results demonstrated that single nucleotide polymorphisms (SNPs) in a gene that is homologous to